Clinical Trials
40 trialsNCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT03554109 2025-02-21
TNBC
ImmunityBio, Inc.
Phase 2 Withdrawn
NCT02299999 2025-01-15
SAFIR02_Breast
UNICANCER
Phase 2 Active not recruiting
NCT00036868 2024-03-08
Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00525759 2023-11-24
ANZAC
Sheffield Teaching Hospitals NHS Foundation Trust
Phase 2 Completed
NCT01036087 2023-03-30
Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00773695 2023-01-09
A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT01779050 2022-11-01
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells
Washington University School of Medicine
Phase 2 Terminated
NCT02897050 2022-04-20
Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Suspended
NCT02400567 2022-03-15
NeoPAL
UNICANCER
Phase 2 Completed
NCT02742051 2021-09-23
A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Completed
NCT01593020 2021-09-22
Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02132949 2021-09-17
BERENICE
Hoffmann-La Roche
Phase 2 Completed
NCT01220128 2021-05-25
INDUCT
GlaxoSmithKline
Phase 2 Terminated
NCT01855828 2020-03-31
Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer
Yale University
Phase 2 Completed
NCT00820547 2019-10-22
Beverly1
UNICANCER
Phase 2 Completed
NCT02506777 2019-09-04
MBC1
N.N. Petrov National Medical Research Center of Oncology
Phase 2 Unknown
NCT00015886 2018-08-13
Combination Chemotherapy in Treating Women With Breast Cancer That is Metastatic or Cannot be Treated With Surgery
Wake Forest University Health Sciences
Phase 2 Completed
NCT00559845 2018-04-09
A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT02365805 2017-03-13
BERNAQ
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Phase 2 Completed
NCT00499603 2016-11-01
Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Unknown
NCT02846428 2016-07-27
To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT00429299 2016-03-22
CHERLOB
GlaxoSmithKline
Phase 2 Completed
NCT01985841 2015-10-08
Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer
Hellenic Oncology Research Group
Phase 2 Terminated
NCT01658033 2015-09-09
Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) Patients
Fudan University
Phase 2 Completed
NCT00756470 2014-11-17
Phase II Neoadjuvant in Inflammatory Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00425516 2014-10-01
Breast Cancer Treated by Neoadjuvant Chemotherapy
Centre Jean Perrin
Phase 2 Completed
NCT02225652 2014-08-26
A Phase II Study of Dose Density Regimen With Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days With Filgrastim Support Followed by Weekly Paclitaxel in Women With Primary Breast Cancer.
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Completed
NCT02115152 2014-04-15
Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer
Guangxi Medical University
Phase 2 Unknown
NCT00933517 2014-03-21
TVA
Centre Jean Perrin
Phase 2 Completed
NCT00012311 2014-01-06
Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone in Treating Women With Stage IV Breast Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00002498 2013-12-18
Combination Chemotherapy Compared With Mitoxantrone in Treating Older Patients With Advanced Breast Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00533936 2013-08-26
Trastuzumab or Observation After Combination Chemotherapy and Trastuzumab in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00003953 2013-01-28
Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01231802 2012-07-17
Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer
Adherex Technologies, Inc.
Phase 2 Unknown
NCT00124111 2010-02-26
A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast Cancer
Amgen
Phase 2 Completed
NCT00003135 2009-04-30
Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00033683 2009-02-09
Combination Chemotherapy in Treating Women With Resected Breast Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00010075 2008-07-24
Combination Chemotherapy in Treating Older Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00001498 2008-03-04
A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed